Accord Study Group, Accord Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363(3):233-44. https://www.ncbi.nlm.nih.gov/pubmed/20587587
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380(1):11-22. https://www.ncbi.nlm.nih.gov/pubmed/30415628
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 2022. https://www.ncbi.nlm.nih.gov/pubmed/36342113
Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol 2011;6(1):9-20. https://www.ncbi.nlm.nih.gov/pubmed/26207146
Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine -3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation 2021;144(25):1981-90. https://www.ncbi.nlm.nih.gov/pubmed/34612056
Levin A, Duncan L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, et al. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol 2000;53(2):140-6. https://www.ncbi.nlm.nih.gov/pubmed/10711416
Triglyceride Coronary Disease Genetics Consortium & Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375(9726):1634-9. https://www.ncbi.nlm.nih.gov/pubmed/20452521
